Development of mimetic peptide as a potential anticancer drug
Category: Pharmaceutical
Exhibitor: NATIONAL SUN YAT-SEN UNIVERSITY
Booth No: N009
Characteristic
Fusion mimetic peptide Tat-GBRL2H2 is able to enter cancer cells to inhibit ATG4B and cell viability, further promotes cancer cell death. The peptide also suppresses tumor formation in xenografted mouse model.
Other Products
Products you may be interested in
Highest Rated Products